Satisfai and Virgo will merge expertise with Alimentiv to attain AI-driven precision imaging’s full potential in a GI trial space.

artificial-intelligence-g63058bed3_1280-1038x778.jpg.webp

Satisfai Health and Virgo Surgical Video Solutions have entered a strategic collaboration with Alimentiv to leverage artificial intelligence (AI)-powered technology to boost clinical trials in inflammatory bowel disease (IBD) and other gastrointestinal (GI) diseases.

The partnership will transform central reading, capturing of data, decision support, and the recruitment of patients in the clinical trial domain for IBD and associated GI ailments. 

Satisfai is an artificial intelligence solutions developer for the gastroenterology sector while Virgo focuses on endoscopy video capture technology. Alimentiv is a contract research organisation (CRO) in gastroenterology. 

 Satisfai and Virgo will merge their capabilities to work along with Alimentiv to reach the maximum potential of AI-driven precision imaging in the GI clinical trials space.

The alliance will offer special access to the SmartScore Central Reading tool of Satisfai and a completely integrated, Cloud-based, hands-free, high-definition video-capture fleet of Virgo to Alimentiv to continue its leadership in GI trials.

The partnership will also offer pharmaceutical and biotech sponsors access to the continuing development of new endpoints, scalable solutions, and scoring methodologies to bring new treatments to the market rapidly.

Alimentiv CEO Jeff Smith said: “This synergy of Satisfai and Virgo with Alimentiv is a positive development for patients with IBD and the drug development space. 

“Clinical trials have many pain points, and this strategic partnership will enable advances in improving the efficiency of clinical trials and make some significant changes to how trials are run.”

 In September this year, Virgo signed a strategic partnership with 83bar to launch a new Constellation Platform for recruiting patients into trials.
Satisfai, Virgo, and Alimentiv to boost trials using AI-powered technology

Leave a Reply

Your email address will not be published. Required fields are marked *

Visit Us On TwitterVisit Us On Google PlusVisit Us On LinkedinVisit Us On Facebook